Not a Member? Register Now
Email this page
Send the page "" to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
FDA Date: 12/08/2017
Emtricitabine/tenofovir disoproxil fumarate REMS
Goals of the emtricitabine/tenofovir disoproxil fumarate REMS Program
The goals of the REMS for TRUVADA for a Pre-Exposure Prophylaxis (PrEP) Indication are:To inform and educate prescribers and uninfected individuals at high risk for acquiring HIV-1 infection about:• The importance of strict adherence to the recommended dosing regimen• The importance of regular monitoring of HIV-1 serostatus to avoid continuing to take TRUVADA for a PrEP indication, if seroconversion has occurred, to reduce the risk of development of resistant HIV-1 variants• The fact that TRUVADA for a PrEP indication must be considered as only part of a comprehensive prevention strategy to reduce the risk of HIV-1 infection and that other preventive measures should also be used
• Elements to Assure Safe Use